AKT1 and breast carcinoma: In a similar study, the wogonin derivative LW‐213, which accelerates G2/M phase cell cycle arrest in breast cancer preclinical settings by inhibiting the Akt/GSK‐3/β‐catenin signaling pathway, was found to have anticancer characteristics (El‐Hafeez et al. 2019).